09:01 AM EDT, 09/29/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said Monday that it has been granted Orphan-Drug designation from Japan's Ministry of Health, Labor and Welfare for DYNE-251 to treat Duchenne Muscular Dystrophy.

The designation is intended for drugs that treat rare diseases affecting fewer than 50,000 patients in Japan, and includes subsidies for development costs and potential market exclusivity for up to 10 years, the biotech company said.